denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Sponsor: by educational grants from Bristol-Myers Squibb and Taiho Oncology. Provided by Clinical Care Options, LLC.
Program: Satellite Symposia
Hematology Disease Topics & Pathways:
Anemias, Biological, Adult, Diseases, Therapies, Elderly, MDS, cellular interactions, Biological Processes, immunotherapy, erythropoiesis, Study Population, Myeloid Malignancies, signal transduction
Hematology Disease Topics & Pathways:
Anemias, Biological, Adult, Diseases, Therapies, Elderly, MDS, cellular interactions, Biological Processes, immunotherapy, erythropoiesis, Study Population, Myeloid Malignancies, signal transduction
Friday, December 4, 2020: 3:00 PM-6:00 PM
Chair:
Rami S. Komrokji, MD, H. Lee Moffitt Cancer Center and Research Institute
Disclosures:
Komrokji: Agios: Honoraria, Speakers Bureau; AbbVie: Honoraria; BMS: Honoraria, Speakers Bureau; JAZZ: Honoraria, Speakers Bureau; Novartis: Honoraria; Acceleron: Honoraria; Geron: Honoraria; Incyte: Honoraria.
Speakers:
Guillermo Garcia-Manero, MD, The University of Texas MD Anderson Cancer Center
and
Jamile M. Shammo, MD, Rush Univ. Med. Ctr.
Disclosures:
Garcia-Manero: Amphivena Therapeutics: Research Funding; Celgene: Consultancy, Honoraria, Research Funding; H3 Biomedicine: Research Funding; Astex Pharmaceuticals: Consultancy, Honoraria, Research Funding; Acceleron Pharmaceuticals: Consultancy, Honoraria; Novartis: Research Funding; Bristol-Myers Squibb: Consultancy, Research Funding; Helsinn Therapeutics: Consultancy, Honoraria, Research Funding; Jazz Pharmaceuticals: Consultancy; Onconova: Research Funding; Genentech: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; AbbVie: Honoraria, Research Funding; Merck: Research Funding. Shammo: Sanofi: Speakers Bureau; Agios: Consultancy; Novartis: Consultancy; Regeneron: Consultancy; Incyte: Consultancy, Research Funding, Speakers Bureau; BMS: Consultancy, Research Funding, Speakers Bureau; Alexion: Consultancy, Research Funding, Speakers Bureau; Celgene: Consultancy, Research Funding, Speakers Bureau; Takeda: Current equity holder in publicly-traded company; Onconova: Research Funding; Abbive: Current equity holder in publicly-traded company; Baxter: Current equity holder in publicly-traded company; Apellis: Consultancy.
New science has driven innovative medical practice in the management of myelodysplastic syndromes (MDS) with emerging efficacy and safety data on hypomethylating agents (HMAs), erythropoiesis-stimulating agents, immunosuppressants, and lenalidomide. This webinar will focus on evolving therapeutic standards, and expert faculty will provide practical insights for disease and supportive care management of MDS. Each section of the webinar will include a case review and didactic presentation by an expert faculty member, followed by a moderated panel discussion and audience Q&A session. Faculty will discuss key clinical questions, available evidence, and challenges that affect therapeutic decisions as well as their individual treatment recommendations for each case. Throughout the webinar, learners will be able to vote on case scenarios and submit questions to the panel for their consideration. Discussion topics will include:
- Novel Therapeutic Approaches for the Treatment of MDS-Associated Anemia
- Novel Therapeutic Approaches for the Treatment of MDS
- Novel Therapeutic Approaches for the Treatment of Relapsed/Refractory MDS
- Future Directions and Key Ongoing Clinical Trials
See more of: Satellite Symposia